Stem-Cell Transplantation

Low-dose CY/TBI/SCT regimen effective against Fanconi anemia + MDS/AML

Published in Blood Weekly, February 26th, 2004

A regimen of low-dose CY, TBI and SCT is safe and effective for FA + MDS/AML patients.

In a recent study from Saudi Arabia, "[f]ive patients with confirmed Fanconi anemia (FA) and myelodysplasia and/or leukemia underwent stem-cell transplantation (SCT) from related donors".

"The median age at SCT was 12.6 year (range, 6.2-15 years)," noted M. Ayas and coauthors working at King Faisal Specialist Hospital and Research Center in Riyadh. "Conditioning regimen consisted of cyclophosphamide (CY) 5mg/kg/day i.v. for four days, total body irradiation (TBI) 450cGy in a single dose. Graft-versus-host disease (GVHD) prophylaxis was with cyclosporine and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2004-02-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry